Faron Pharmaceuticals Oy, a clinical stage biopharmaceutical company, is actively negotiating to receive a waiver from IPF Fund II SCA, SICAV-FIAR and unblock pledged bank accounts. The company is also considering alternative short- and long-term financing options. As part of the long-term financing arrangements, the Board of Directors intends to propose an authorization for a rights issue at the Annual General Meeting. The notice for the Annual General Meeting will be published separately at a later date.

For more information, the company has provided contact details for investor inquiries in the US and Europe. Additionally, the company has listed its Nomad and Certified Adviser on Nasdaq First North, along with contact information for ICR Consilium.

The announcement also includes a disclaimer that it is not for publication or distribution in the United States and that the rights have not been and will not be registered under the United States Securities Act of 1933.

Faron Pharmaceuticals Ltd is a global, clinical-stage biopharmaceutical company focused on developing novel immunotherapies to tackle cancers. Its lead asset, bexmarilimab, is a novel anti-Clever-1 humanized antibody being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

The announcement also includes forward-looking statements, emphasizing that they are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the company's future growth, results of operations, and performance.